Loading patent…
AssigneesThe Brigham and Women's Hospital, Inc., Beth Israel Deaconess Medical Center, Inc.
InventorsVijay K. Kuchroo, Terry Strom, Eugene K. Cha, Sumone Chakravarti, Catherine Sabatos, Chen Zhu, Xin Xiao Zheng, Alberto Sanchez-Fueyo
Estimating the term…
The invention relates to isolated polypeptides and nucleic acids encoding polypeptides which comprise a tim-3 IgV domain and a tim-3 intracellular domain, wherein the polypeptides do not comprise a tim-3 mucin domain or a tim-3 transmembrane domain. In addition, the invention relates to methods of modulating immune responses in a subject, comprising administering to the subject a therapeutically effective amount of an agent that modulates tim-3 activity. Immune responses include, but are not limited to, immune tolerance, transplantation tolerance, Th1 responses and Th2 responses.
(canceled)
A method for increasing a Th1-mediated immune response in a subject, the method comprising administering an antibody or antigen-binding fragment thereof that binds to a galectin-9 polypeptide and decreases tim-3 activity, thereby increasing a Th1-mediated immune response in the subject.
Dependencies are inferred from the claim text.